If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
658.00    -19.00 (-2.81%)
Bid:
656.00
Ask:
660.00
Spread: 4.00 (0.61%)
Market Cap: £573.28m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

AGM & Q1 Interim Management Statement

10 Feb 2023 07:00

RNS Number : 5110P
Victrex PLC
10 February 2023
 
 

10 February 2023

Victrex plc - AGM & Q1 Interim Management Statement

'A steady start: pricing ahead of expectations and revenue up 6%, despite volume softness'

Victrex plc is an innovative world leader in high performance polymer solutions, delivering sustainable products which enable environmental and societal benefit in multiple end-markets. Today's Interim Management Statement (IMS) covers the first quarter of FY 2023 from 1 October 2022 to 31 December 2022.

 

Overall, the Group saw a steady start, in what is typically the seasonally weakest quarter. Average selling prices (ASP) were ahead of expectations, with good momentum from price increases and surcharge pricing. This helped to drive revenue up 6%, despite an 8% decline in Q1 volume; slightly softer than anticipated.

Highlights

· Q1 Group revenue £78.8m up 6% (Q1 2022: £74.6m)

· ASP up 14% at £83/kg and slightly ahead of expectations; driven by sales mix, annualised price increases, surcharge pricing and currency

· Q1 Group sales volume of 948 tonnes down 8% on the prior year (Q1 2022: 1,025 tonnes)

· Supporting TechnipFMC for Brazil scale-up ahead of bid outcome for Magma pipe opportunity

· Share buybacks now included alongside special dividends for excess cash return options, following shareholder engagement

 

End market performance

Q1 performance reflected reduced activity across several Industrial end markets, particularly in Europe, together with some normalisation within Value Added Resellers (VAR) after a period of strong growth. The Group saw growth in Aerospace and Automotive during the period, which was offset by weakness in Electronics and Energy & Industrial.

 

In Medical, we continue to see a good performance. Q1 revenue was strongly ahead of the comparative period, which included the impact of Covid-19 variants and lockdowns in the US, in Europe and Asia.

 

Mega-programmes

The Group has an attractive portfolio of short, medium and long-term growth opportunities, including seven 'mega-programmes' offering potentially game changing growth opportunities. 

 

In our Magma mega-programme, which is based on thermoplastic composite pipe for the energy industry using Victrex PEEK, Victrex composite tape and Victrex's pipe extrusion know-how, we continue to support TechnipFMC for qualification and scale-up at a new facility in Brazil. Bid outcomes for a key offshore programme in Brazil are anticipated over the coming months, offering the potential opportunity for significant annual volumes, over a multi-year period.

 

In our PEEK Knee mega-programme, we have seen further strong progress. Patient recruitment to the Maxx Orthopaedics clinical trial is largely complete, with 33 implanted patients. Ten patients have passed the primary end-point for the clinical trial (15 months), with no issues or intervention required. Two patients will pass the two-year implant stage this month. In Trauma, In2Bones has continued to make strong progress, with our PEEK composite based Trauma plates now being implanted in over 80 patients.

 

Financial position

Victrex retains a highly cash generative business model, supporting growth investment alongside attractive shareholder returns. Available cash of £60.8m at 31 December 2022 (excluding £2.3m of cash ringfenced in our Chinese subsidiaries), is prior to payment of the 2022 final dividend on 17 February. 

 

Outlook

Jakob Sigurdsson, Chief Executive of Victrex, said: "Expectations for the full year are unchanged at this early stage. We are encouraged by modest revenue growth, a better sales mix and improved selling prices. We also continue to make good progress in recovering energy and raw material inflation.

 

"However, the Group saw softer volumes during Q1 and the macro-economic environment remains uncertain, with ongoing weakness in several end-markets. In line with Victrex's historic performance, we remain well positioned for when end-markets improve.

 

"With sustainable products and a strong pipeline of growth opportunities, our Polymer & Parts strategy keeps us well positioned for the medium to long-term."

 

Analyst & investor conference call

A conference call with management will take place this morning, Friday 10th February 2023, at 08.30am GMT. Access to the call is via the following link: https://cossprereg.btci.com/prereg/key.process?key=PYTAVPVQF

 

Annual General Meeting

Victrex's Annual General Meeting will also be held today, starting at 11.00am GMT and taking place at JP Morgan, 1 John Carpenter Street, London EC4Y 0JP.

 

Victrex plc:

Andrew Hanson, Director of Investor Relations, Corporate Communications & ESG +44 (0)7809 595831

Ian Melling, Chief Financial Officer +44 (0)1253 897700

Jakob Sigurdsson, Chief Executive +44 (0)1253 897700

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to energy operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, enable environmental and societal benefit for our customers and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRFUPUPCPUPWGRB
Date   Source Headline
30th Aug 20138:33 amRNSTotal Voting Rights
19th Aug 20134:07 pmRNSDirector/PDMR Shareholding
2nd Aug 20138:48 amRNSHolding(s) in Company
29th Jul 20137:56 amRNSDirector Declaration
25th Jul 20137:00 amRNSInterim Management Statement
17th Jul 20131:46 pmRNSDirector/PDMR Shareholding
2nd Jul 201310:54 amRNSHolding(s) in Company
2nd Jul 20137:39 amRNSDirector Declaration
28th Jun 20138:00 amRNSTotal Voting Rights
26th Jun 20139:35 amRNSHolding(s) in Company
25th Jun 201310:43 amRNSHolding(s) in Company
24th Jun 20132:33 pmRNSHolding(s) in Company
21st Jun 20139:13 amRNSHolding(s) in Company
18th Jun 20134:41 pmRNSDirector/PDMR Shareholding
7th Jun 201312:26 pmRNSHolding(s) in Company
5th Jun 20132:02 pmRNSDirector/PDMR Shareholding
3rd Jun 20131:50 pmRNSBlocklisting Interim Review
31st May 20131:49 pmRNSTotal Voting Rights
28th May 20139:02 amRNSHolding(s) in Company
28th May 20137:00 amRNSHalf Yearly Report
20th May 20133:34 pmRNSHolding(s) in Company
17th May 20131:39 pmRNSDirector/PDMR Shareholding
16th May 201310:35 amRNSHolding(s) in Company
14th May 20139:58 amRNSHolding(s) in Company
30th Apr 20133:53 pmRNSTotal Voting Rights
24th Apr 20134:24 pmRNSHolding(s) in Company
22nd Apr 20134:14 pmRNSHolding(s) in Company
22nd Apr 20134:02 pmRNSHolding(s) in Company
17th Apr 20131:54 pmRNSDirector/PDMR Shareholding
16th Apr 20134:34 pmRNSHolding(s) in Company
9th Apr 20137:00 amRNSTrading Statement
3rd Apr 20133:01 pmRNSHolding(s) in Company
28th Mar 20133:00 pmRNSTotal Voting Rights
22nd Mar 20139:51 amRNSHolding(s) in Company
21st Mar 201310:25 amRNSHolding(s) in Company
20th Mar 201312:28 pmRNSDirector/PDMR Shareholding
13th Mar 201312:20 pmRNSHolding(s) in Company
28th Feb 20133:19 pmRNSTotal Voting Rights
28th Feb 20132:49 pmRNSDirector/PDMR Shareholding
27th Feb 201311:05 amRNSHolding(s) in Company
26th Feb 20139:32 amRNSHolding(s) in Company
20th Feb 201311:38 amRNSDirector/PDMR Shareholding
5th Feb 20134:24 pmRNSResult of AGM
5th Feb 20137:00 amRNSAGM and Interim Management Statement
4th Feb 201311:42 amRNSHolding(s) in Company
31st Jan 201312:47 pmRNSTotal Voting Rights
29th Jan 201312:46 pmRNSHolding(s) in Company
23rd Jan 201312:23 pmRNSHolding(s) in Company
17th Jan 20134:13 pmRNSDirector/PDMR Shareholding
8th Jan 201310:24 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.